Managing Myeloma
- 2015-03-12 - Important Reminder! International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma - The Lancet Oncology #IMWG
- 2015-03-01 - Carfilzomib Out Performs Bortezomib in Head-to-Head ENDEAVOR Trial: Relapsed/Refractory Patients Who Were Progressing After Three Previous Therapies -- The Street
- 2015-02-23 - Breaking News: Novartis receives FDA approval of Panobinostat (Farydak(R)), the first HDAC inhibitor for patients with multiple myeloma -- Market Watch
- 2015-02-23 - FDA approves Panobinostat (Farydak) for treatment of multiple myeloma -- U.S. FDA News Release
- 2015-02-20 - The European Commission has approved Lenalidomide for adults with previously untreated MM who are not eligible for transplant -- Pharma Times
- 2015-02-18 - BREAKING NEWS!!! FDA Approves Frontline Lenalidomide for Multiple Myeloma - OncLive
- 2015-02-10 - Takeda Announces That the First Interim Analysis of the Phase 3 Study of Oral Ixazomib in Patients with Relapsed or Refractory Multiple Myeloma Met the Primary Endpoint of Improvement in Progression-Free Survival
- 2015-01-19 - Additional treatment helps recurrent myeloma - Irish Medical Times
- 2015-01-19 - Higher Bortezomib Dose Upped Multiple Myeloma Survival - CancerNetwork/journal Oncology
- 2015-01-19 - Challenges in the Diagnosis of Symptomatic Multiple Myeloma - Medpage Today
- 2015-01-13 - Several Cancer Therapies Up for FDA Review in 2015 (Three for Multiple Myeloma) - CureToday
- 2015-01-03 - Immune cell inhibition by SLAMF7 is mediated by mechanism requiring Src kinases, CD45 and SHIP-1 defective in multiple myeloma cells -- MCB
- 2014-11-16 - Important Consensus Update from the IMWG: Practice Change: International Myeloma Working Group (IMWG) updated criteria for the diagnosis of multiple myeloma -- Lancet Oncology
- 2014-11-06 - News Flash: ODAC Votes Against Panobinostat in Multiple Myeloma -- OncLive
- 2014-09-08 - NEWS FLASH! NCCN Guidelines for Multiple Myeloma Have Been Updated (Version 1.2015): Lenalidomide/low-dose dex to be given continuously in Non-transplant patients (Cat 1) -- NCCN.org